Literature DB >> 2545860

Potent stimulation of myofilament force and adenosine triphosphatase activity of canine cardiac muscle through a direct enhancement of troponin C Ca++ binding by MCI-154, a novel cardiotonic agent.

Y Kitada1, M Kobayashi, A Narimatsu, Y Ohizumi.   

Abstract

In the present study we have analyzed a likely biochemical mechanism underlying the Ca++-sensitizing action of MCI-154 (6-[4-(4'-pyridyl)aminophenyl)-4,5-dihydro-3(2H)-pyridazinone hydrochloride), a novel cardiotonic agent, on the contractile protein system. MCI-154 (10(-7) to 10(-4) M) enhanced the tension development induced by -log molar-free Ca++ concentration (pCa) 5.8 in chemically skinned fiber from the canine right ventricular muscle in a concentration-dependent manner. At pCa 7.0, MCI-154 (10(-7) to 10(-4) M) markedly increased adenosine triphosphatase (ATPase) activities of canine myofibrils and reconstituted actomyosin. In myofibrils and reconstituted actomyosin, MCI-154 (10(-7) to 10(-4) M) caused a parallel shift of the pCa-ATPase activity relation curve to the left without affecting the maximum activity, suggesting an increase in Ca++ sensitivity. MCI-154 (10(-8) to 10(-4) M) had little effect on actin-activated, Mg++, Ca++ and (K+, EDTA)-ATPase activities of myosin. Ca++ binding to cardiac myofibrils or purified cardiac troponin was increased by 10(-4) M MCI-154. These results suggest that MCI-154 enhances Ca++ binding to cardiac troponin C to elevate the Ca++ sensitivity of myofilaments and thus may cause a positive inotropic action in cardiac muscle. MCI-154 may provide a valuable tool for studying the molecular mechanism by which Ca++ regulates the contractile system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545860

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  Targeting the sarcomere to correct muscle function.

Authors:  Peter M Hwang; Brian D Sykes
Journal:  Nat Rev Drug Discov       Date:  2015-04-17       Impact factor: 84.694

2.  Mg-ATPase and Ca+ activated myosin AtPase activity in ventricular myofibrils from non-failing and diseased human hearts--effects of calcium sensitizing agents MCI-154, DPI 201-106, and caffeine.

Authors:  Chukwuka Okafor; Ronglih Liao; Cynthia Perreault-Micale; Xiaoping Li; Toshiro Ito; Anna Stepanek; Angelia Doye; Pieter de Tombe; Judith K Gwathmey
Journal:  Mol Cell Biochem       Date:  2003-03       Impact factor: 3.396

Review 3.  Calcium sensitising agents in heart failure.

Authors:  L Mathew; S D Katz
Journal:  Drugs Aging       Date:  1998-03       Impact factor: 3.923

4.  Cardiotonic actions of selective phosphodiesterase inhibitors in rat isolated ventricular cardiomyocytes.

Authors:  E J Kelso; B J McDermott; B Silke
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

Review 5.  Novel myosin-based therapies for congenital cardiac and skeletal myopathies.

Authors:  Julien Ochala; Yin-Biao Sun
Journal:  J Med Genet       Date:  2016-07-13       Impact factor: 6.318

6.  The calcium sensitizer drug MCI-154 binds the structural C-terminal domain of cardiac troponin C.

Authors:  Monica X Li; Shorena Gelozia; Gaddafi I Danmaliki; Yurong Wen; Philip B Liu; M Joanne Lemieux; Frederick G West; Brian D Sykes; Peter M Hwang
Journal:  Biochem Biophys Rep       Date:  2018-11-01

7.  Small Molecule RPI-194 Stabilizes Activated Troponin to Increase the Calcium Sensitivity of Striated Muscle Contraction.

Authors:  Zabed Mahmud; Svetlana Tikunova; Natalya Belevych; Cory S Wagg; Pavel Zhabyeyev; Philip B Liu; David V Rasicci; Christopher M Yengo; Gavin Y Oudit; Gary D Lopaschuk; Peter J Reiser; Jonathan P Davis; Peter M Hwang
Journal:  Front Physiol       Date:  2022-06-08       Impact factor: 4.755

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.